Karim Fizazi · Person

Karim Fizazi is one of the most influential prostate cancer trialists of the past two decades, leading LATITUDE (abiraterone in high-risk metastatic hormone-sensitive disease), PEACE-1 (triplet therapy), and studies of radium-223 and PSMA radioligands.

Role

Head of Medical Oncology, Gustave Roussy; Professor, Paris-Saclay

Institution

Gustave Roussy

Specialisms

Prostate cancerGenitourinary oncologyHormone therapyRadioligand therapy

Profiles

PubMed

Papers

2top

Title	Journal	Year
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer (LATITUDE)	NEJM	2017
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1)	Lancet	2022

Key papers

1top

rctNew England Journal of Medicine 2021changed practice

VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer

Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).